NEOG — Neogen Corporation

Is NEOG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of October 3, 2026

Neogen Corporation (NEOG) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $12.15. The rating moved from Overbought to Oversold on September 30, 2026.

See all oversold Healthcare stocks →

AI analysis

Neogen Corporation shows a steady commercial franchise in food and animal safety testing with recurring revenue drivers and mostly constructive recent disclosures. Near-term market conditions are cautious, with macro and supply-chain risks likely to dominate price action; absent fresh catalysts, expect muted directional moves. Key sensitivities include margin pressure from input costs, regulatory shifts, and competitive dynamics that will determine medium-term upside.

Key factors

  • Established market position in food and animal safety testing with diversified product lines (testing kits, reagents, and diagnostics) that support recurring revenue.
  • Recent SEC filings show a predominance of positive disclosures, suggesting stable corporate governance and ongoing operational activity.
  • Defensive demand profile for certain product categories may provide relative shelter during short-term market risk-off episodes.
  • Limited near-term macro catalysts as markets show muted conviction; earnings-season commentary and rate-path uncertainty are currently dominating sentiment.
  • Exposure to global supply-chain dynamics and input-cost pressures that could compress margins or limit timely product delivery.
  • Stable end-market demand from food processors and veterinary channels, supporting steady cashflow but slower growth compared with high-growth biotech peers.

Risks

  • Broader risk-off market environment and light trading volumes could depress the share price independently of fundamentals.
  • Supply-chain disruptions or input cost inflation could hurt gross margins and shipment timings.
  • Regulatory changes or increased testing standards could require incremental CAPEX or R&D spend.
  • Intensifying competition from larger diagnostics firms or lower-cost entrants could pressure pricing and market share.
  • Reliance on certain large customers or distribution partners creates customer-concentration risk.
  • Unclear near-term revenue catalysts and potential for slower organic growth relative to market expectations.

See today's live rating, score and targets

Members see the live hourly rating for NEOG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.